Then, an isozyme-selective MTHFD2 inhibitor, DS18561882, was discovered to repress the proliferation of breast cancer cell lines and the tumor growth in a mouse xenograft model with breast carcinoma upon oral administration [32]. This evidence concerns the gene MTHFD2 and breast carcinoma.